世界のがん生物学的製剤市場2021-2031

■ 英語タイトル:Cancer Biologics Market Report 2021-2031

調査会社visiongain社が発行したリサーチレポート(データ管理コード:VGA21MA032)■ 発行会社/調査会社:visiongain
■ 商品コード:VGA21MA032
■ 発行日:2021年2月
■ 調査対象地域:グローバル
■ 産業分野:医薬品
■ ページ数:376
■ レポート言語:英語
■ レポート形式:PDF
■ 納品方式:Eメール(受注後24時間以内)
■ 販売価格オプション(消費税別)
Sigle User(1名様閲覧用、1年間、印刷不可)USD5,199 ⇒換算¥769,452見積依頼/購入/質問フォーム
Global Site License(法人閲覧用、1年間、印刷可)USD9,099 ⇒換算¥1,346,652見積依頼/購入/質問フォーム
※visiongain社発行の調査レポートは、Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。

販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能)
visiongain社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[世界のがん生物学的製剤市場2021-2031]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

本調査レポートでは、世界のがん生物学的製剤の市場について調査・分析し、レポート概要、イントロダクション、市場概要、治療種類別(化学療法、標的療法、免疫療法、ホルモン療法、その他治療法)分析、疾患別(乳がん、子宮頸がん、結腸がん、直腸がん、胃がん)分析、生物学的医薬品別(ベバシズマブ、トラスツズマブ、トラスツズマブエムタンシン、ペルツズマブ、リツキシマブ)分析、エンドユーザー別(病院、専門クリニック、がん・放射線治療センター)分析、地域別分析、企業情報などの項目を掲載しています。
・レポート概要
・イントロダクション
・市場概要
・世界のがん生物学的製剤市場規模:治療種類別(化学療法、標的療法、免疫療法、ホルモン療法、その他治療法)
・世界のがん生物学的製剤市場規模:疾患別(乳がん、子宮頸がん、結腸がん、直腸がん、胃がん)
・世界のがん生物学的製剤市場規模:生物学的医薬品別(ベバシズマブ、トラスツズマブ、トラスツズマブエムタンシン、ペルツズマブ、リツキシマブ)
・世界のがん生物学的製剤市場規模:エンドユーザー別(病院、専門クリニック、がん・放射線治療センター)
・世界のがん生物学的製剤市場規模:地域別
・企業情報

This report is intended to provide an in-depth analysis of the latest trends prevailing in the cancer biologics market and its growth and development in the next decade. The changing demographics of the world population, increasing cancer prevalence, developing healthcare infrastructure, emerging economies, consumer spending behaviour, per capita income, macroeconomic factors, rising GDPs, and the reformation in laws and regulations are trend setting factors, which will affect the market.

Why Cancer Biologics Market is Growing?

The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies. Moreover, rising number of pre-screening programs for cancer detection using liquid biopsy are expected to provide new market opportunities for cancer biologics in near future.

What are the Market Driving Factors?
• Rising Cancer Prevalence Worldwide
• Increasing Ageing Population in Developed as well as Developing Economies
Key Challenges for Cancer Biologics Market
• Shortage of Skilled Workforce in the Biopharmaceutical Industry
• High Cost Associated with Biopharmaceutical Drug Manufacturing
What are the Market Opportunities?
• Increasing R&D Spending of Biopharmaceutical Companies
• Future Perspective in Oncology Industry
Why you Should buy this Report?

Apart from market estimation and forecast to 2031 the report covers below mentioned important factors to offer in-depth analysis of cancer biologics industry
• SWOT Analysis
• Porter’s Five Forces Model
• European Oncology Market Trends
• Global Oncology Spending, 2016 – 2031
• Disease Prevalence and Incidence in Europe by Country
• EMA Approved Biologics in Oncology
• Biosimilars and R&D Biologics in Development
This report includes data analysis and invaluable insight into how COVID-19 will affect your industry. Access this report today.

What are the Leading Companies Operating in the Market?
• AbbVie Inc
• F.Hoffman La Roche
• GlaxoSmithKline
• Eli Lilly and Company
• Amgen
• Johnson & Johnson
• Merck & Co.
• Pfizer
Market Segmentation and Scope

Cancer Biologics Market by Treatment
• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Hormonal Therapy
• Others
Cancer Biologics Market by Indication
• Breast cancer
• Cervical cancer
• Colon and rectal cancer
• Gastric cancer
• Lung cancer
• Ovarian cancer
• Renal cell cancer
• Melanoma
Cancer Biologics Market by Biologic Drug
• Bevacizumab
• Trastuzumab
• Trastuzumab emtansine
• Pertuzumab
• Rituximab
• Cetuximab
• Panitumumab
• Ramucirumab
• Necitumumab
• Pembrolizumab
• Atezolizumab
• Durvalumab
• Nivolumab
• Ipilimumab
Cancer Biologics Market by End User
• Hospitals
• Specialty Clinics
• Cancer and Radiation Therapy Centers
Europe Cancer Biologics Market
• UK Cancer Biologics Market
• Germany Cancer Biologics Market
• France Cancer Biologics Market
• Italy Cancer Biologics Market
• Spain Cancer Biologics Market
• Portugal Cancer Biologics Market
• Poland Cancer Biologics Market
• Hungary Cancer Biologics Market
• Czech Republic Cancer Biologics Market
• Slovakia Cancer Biologics Market
• Slovenia Cancer Biologics Market
• Romania Cancer Biologics Market
• Bulgaria Cancer Biologics Market
• Croatia Cancer Biologics Market
• Baltic States Cancer Biologics Market
• Serbia Cancer Biologics Market

*** レポート目次(コンテンツ)***

1. Report Overview
1.1. Global Cancer Biologics Market Overview
1.2. Why You Should Read This Report
1.3. How This Report Delivers
1.4. Key Questions Answered by This Analytical Report
1.5. Who Is This Report For?
1.6. Methodology
1.6.1. Primary Research
1.6.2. Secondary Research
1.6.3. Market Evaluation & Forecasting Methodology
1.7. Frequently Asked Questions (FAQ)
1.8. Associated Visiongain Reports
1.9. About Visiongain
2. Introduction to the Cancer Biologics Market
2.1. Cancer Biologics Market Definition
2.2. Treatments used in Cancer Biologics Industry
2.2.1. Chemotherapy
2.2.2. Targeted Therapy
2.2.2.1. Monoclonal Antibodies
2.2.2.2. Small-Molecule Drugs
2.2.3. Immunotherapy
2.2.4. Hormonal Therapy
2.3. Cancer Biologics Industry by Indication
2.3.1. Breast Cancer
2.3.2. Cervical Cancer
2.3.3. Colon and Rectal Cancer
2.3.4. Gastric Cancer
2.3.5. Lung Cancer
2.3.6. Ovarian Cancer
2.3.7. Renal Cell Cancer
2.3.8. Melanoma
3. Cancer Biologics Market Overview
3.1. Global Oncology Spending Market Size, Market Analysis and Forecast, 2016-2031
3.2. Global and Regional Cancer Biologics Market, 2021-2031
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Rising Cancer Prevalence Worldwide
3.3.1.2. Increasing Ageing Population in Developed as well as Developing Economies
3.3.2. Market Restraints/Challenges
3.3.2.1. Shortage of Skilled Workforce in the Biopharmaceutical Industry
3.3.2.2. High Cost Associated with Biopharmaceutical Drug Manufacturing
3.3.3. Opportunities
3.3.3.1. Increasing R&D Spending of Biopharmaceutical Companies
3.3.3.2. Future Perspective in Oncology Industry
3.4. Cancer Biologics Market: SWOT Analysis
3.5. Cancer Biologics Market: Porter’s Five Forces Model
3.5.1. Bargaining Power of Buyers
3.5.2. Bargaining Power of Suppliers
3.5.3. Threats of New Entrants
3.5.4. Threats of Substitutes
3.5.5. Competitive Rivalry
3.6. European Oncology Market Trends
3.7. Disease Prevalence and Incidence in Europe
3.7.1. Germany Cancer Incidence and Mortality
3.7.2. UK Cancer Incidence and Mortality
3.7.3. France Cancer Incidence and Mortality
3.7.4. Italy Cancer Incidence and Mortality
3.7.5. Spain Cancer Incidence and Mortality
3.7.6. Portugal Cancer Incidence and Mortality
3.7.7. Poland Cancer Incidence and Mortality
3.7.8. Hungary Cancer Incidence and Mortality
3.7.9. Czech Republic Cancer Incidence and Mortality
3.7.10. Slovakia Cancer Incidence and Mortality
3.7.11. Slovenia Cancer Incidence and Mortality
3.7.12. Romania Cancer Incidence and Mortality
3.7.13. Bulgaria Cancer Incidence and Mortality
3.7.14. Croatia Cancer Incidence and Mortality
3.7.15. Serbia Cancer Incidence and Mortality
3.8. Prescription Distribution of Bevacizumab and Trastuzumab
3.8.1. Prescription Distribution of Bevacizumab
3.8.1.1. Metastatic Colorectal Cancer
3.8.1.2. First-Line Non-Squamous Non–Small Cell Lung Cancer
3.8.1.3. Recurrent Glioblastoma
3.8.1.4. Metastatic Renal Cell Carcinoma
3.8.1.5. Persistent, Recurrent, Or Metastatic Cervical Cancer
3.8.1.6. Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer
3.8.1.7. Hepatocellular Carcinoma
3.8.2. Prescription Distribution of Trastuzumab
3.8.2.1. Adjuvant Breast Cancer
3.8.2.2. Metastatic Breast Cancer
3.8.2.3. Metastatic Gastric Cancer
3.9. EMA Approval, Loss of Exclusivity and Introduction of Biosimilars Impact Analysis
3.10. Patient drop-out rate
3.11. Oncologist Perceptions on Biosimilars
3.12. Barriers to Biologic Treatments and Expected Impact of Cheaper Options on the Market
3.13. Biosimilars and R&D Biologics in Development
4. Global Cancer Biologics Market Analysis and Forecast 2021-2031, by Treatment Type
4.1. Chemotherapy Market Size
4.1.1. Side Effects of Chemotherapy
4.1.2. Cancer Biologics Market Outlook for Chemotherapy: Recovery Scenarios (V, U, L, W)
4.2. Targeted Therapy Market Size
4.2.1. Examples of Targeted Therapies
4.2.2. Targeted Therapies Approved for Specific Types of Cancer
4.2.3. Cancer Biologics Market Outlook for Targeted Therapy: Recovery Scenarios (V, U, L, W)
4.2.4. Tyrosine kinase inhibitors (small molecules) / mTOR, BRAF, etc. receptor targeted agents
4.2.5. Monoclonal antibodies / mAbs (VEGF, HER, DP1, etc. receptor targeted agents)
4.2.6. Antibody-drug conjugates – with mAbs or with a small molecule
4.3. Immunotherapy Market Size
4.3.1. What Does Immunotherapy Treat?
4.3.2. Types of Immunotherapy
4.3.3. Cancer Biologics Market Outlook for Immunotherapy: Recovery Scenarios (V, U, L, W)
4.4. Hormonal Therapy Market Size
4.4.1. Hormone Therapy for Breast Cancer
4.4.2. Hormone Therapy Drugs for Breast Cancer
4.4.3. Breast Cancer and Tamoxifen
4.4.4. Cancer Biologics Market Outlook for Hormonal Therapy: Recovery Scenarios (V, U, L, W)
4.5. Other Treatments Market Size
4.5.1. Are there Vaccines that Prevent Cancer?
4.5.2. Cancer Biologics Market Outlook for Other Treatments: Recovery Scenarios (V, U, L, W)
5. Global Cancer Biologics Market Analysis and Forecast 2021-2031, by Indication
5.1. Breast Cancer Market Size
5.1.1. Node Preservation Reduces Lymphedema Cases
5.1.2. Genomic Testing Minimizes Chemotherapy Exposure
5.1.3. Oral Option for Targeted Therapy
5.1.4. Breast Cancer Statistics, 2020
5.1.5. Cancer Biologics Market Outlook for Breast Cancer: Recovery Scenarios (V, U, L, W)
5.2. Cervical Cancer Market Size
5.2.1. Cancer Biologics Market Outlook for Cervical Cancer: Recovery Scenarios (V, U, L, W)
5.3. Colon and Rectal Cancer Market Size
5.3.1. Drugs Approved for Colon Cancer
5.3.2. Drugs Combinations Used in Colon Cancer
5.3.3. Drugs Approved for Rectal Cancer
5.3.4. Drugs Combinations Used in Rectal Cancer
5.3.5. Cancer Biologics Market Outlook for Colon and Rectal Cancer: Recovery Scenarios (V, U, L, W)
5.4. Gastric Cancer Market Size
5.4.1. Drugs Approved for Gastric Cancer
5.4.2. Drugs Combinations Used in Gastric Cancer
5.4.3. Drugs Approved for Gastroenteropancreatic Neuroendocrine Tumors
5.4.4. Cancer Biologics Market Outlook for Gastric Cancer: Recovery Scenarios (V, U, L, W)
5.5. Lung Cancer Market Size
5.5.1. Drugs Approved for Non-Small Cell Lung Cancer
5.5.2. Drug Combinations Used to Treat Non-Small Cell Lung Cancer
5.5.3. Drugs Approved for Small Cell Lung Cancer
5.5.4. Cancer Biologics Market Outlook for Lung Cancer: Recovery Scenarios (V, U, L, W)
5.6. Ovarian Cancer Market Size
5.6.1. Available Treatments for Ovarian Cancer
5.6.2. What New Treatment Options are Under Development?
5.6.3. Cancer Biologics Market Outlook for Ovarian Cancer: Recovery Scenarios (V, U, L, W)
5.7. Renal Cell Cancer Market Size
5.7.1. Cancer Biologics Market Outlook for Renal Cell Cancer: Recovery Scenarios (V, U, L, W)
5.8. Melanoma Market Size
5.8.1. Drugs Approved for Melanoma
5.8.2. Cancer Biologics Market Outlook for Melanoma: Recovery Scenarios (V, U, L, W)
5.9. Other Indications Market Size
5.9.1. Cancer Biologics Market Outlook for Other Indications: Recovery Scenarios (V, U, L, W)
6. Global Cancer Biologics Market Analysis and Forecast 2021-2031, by Biologic Drugs
6.1. Bevacizumab Market Size
6.1.1. Bevacizumab Similar Biologic Launched in India
6.1.2. Cancer Biologics Market Outlook for Bevacizumab: Recovery Scenarios (V, U, L, W)
6.2. Trastuzumab Market Size
6.2.1. Cancer Biologics Market Outlook for Trastuzumab: Recovery Scenarios (V, U, L, W)
6.3. Trastuzumab emtansine Market Size
6.3.1. Cancer Biologics Market Outlook for Trastuzumab emtansine: Recovery Scenarios (V, U, L, W)
6.4. Pertuzumab Market Size
6.4.1. FDA Accepted Roche’s Biologics License Application
6.4.2. Cancer Biologics Market Outlook for Pertuzumab: Recovery Scenarios (V, U, L, W)
6.5. Rituximab Market Size
6.5.1. Cancer Biologics Market Outlook for Rituximab: Recovery Scenarios (V, U, L, W)
6.6. Cetuximab Market Size
6.6.1. Cancer Biologics Market Outlook for Cetuximab: Recovery Scenarios (V, U, L, W)
6.7. Panitumumab Market Size
6.7.1. Cancer Biologics Market Outlook for Panitumumab: Recovery Scenarios (V, U, L, W)
6.8. Ramucirumab Market Size
6.8.1. Cancer Biologics Market Outlook for Ramucirumab: Recovery Scenarios (V, U, L, W)
6.9. Necitumumab Market Size
6.9.1. Role of Necitumumab in the Treatment of Non–Small Cell Lung Cancer (NSCLC)?
6.9.2. Cancer Biologics Market Outlook for Necitumumab: Recovery Scenarios (V, U, L, W)
6.10. Pembrolizumab Market Size
6.10.1. What Pembrolizumab Is Used For:
6.10.2. Cancer Biologics Market Outlook for Pembrolizumab: Recovery Scenarios (V, U, L, W)
6.11. Atezolizumab Market Size
6.11.1. Atezolizumab Drug Used in below Indiactions
6.11.2. Cancer Biologics Market Outlook for Atezolizumab: Recovery Scenarios (V, U, L, W)
6.12. Durvalumab Market Size
6.12.1. FDA Approved Durvalumab for Extensive-Stage Small Cell Lung Cancer
6.12.2. Cancer Biologics Market Outlook for Durvalumab: Recovery Scenarios (V, U, L, W)
6.13. Nivolumab Market Size
6.13.1. FDA to Review Additional GI Cancer Indications for Nivolumab
6.13.2. Cancer Biologics Market Outlook for Nivolumab: Recovery Scenarios (V, U, L, W)
6.14. Ipilimumab Market Size
6.14.1. Cancer Biologics Market Outlook for Ipilimumab: Recovery Scenarios (V, U, L, W)
7. Global Cancer Biologics Market Analysis and Forecast 2021-2031, by End User
7.1. Hospitals Market Size
7.1.1. Cancer Biologics Market Outlook for Hospitals: Recovery Scenarios (V, U, L, W)
7.2. Specialty Clinics Market Size
7.2.1. Cancer Biologics Market Outlook for Specialty Clinics: Recovery Scenarios (V, U, L, W)
7.3. Cancer and Radiation Therapy Centers Market Size
7.3.1. How is the Cancer Research Institute Involved in the Development of Immunotherapy?
7.3.2. Cancer Biologics Market Outlook for Cancer and Radiation Therapy Centers: Recovery Scenarios (V, U, L, W)
8. Europe Cancer Biologics Market Analysis and Forecast, 2021-2031
8.1. Europe Cancer Biologics Market Size
8.1.1. Europe Cancer Biologics Market Outlook: Recovery Scenarios (V, U, L, W)
8.2. UK Cancer Biologics Market Size
8.3. Germany Cancer Biologics Market Size
8.4. France Cancer Biologics Market Size
8.5. Italy Cancer Biologics Market Size
8.6. Spain Cancer Biologics Market Size
8.7. Portugal Cancer Biologics Market Size
8.8. Poland Cancer Biologics Market Size
8.9. Hungary Cancer Biologics Market Size
8.10. Czech Republic Cancer Biologics Market Size
8.11. Slovakia Cancer Biologics Market Size
8.12. Slovenia Cancer Biologics Market Size
8.13. Romania Cancer Biologics Market Size
8.14. Bulgaria Cancer Biologics Market Size
8.15. Croatia Cancer Biologics Market Size
8.16. Baltic States Cancer Biologics Market Size
8.17. Serbia Cancer Biologics Market Size
8.18. Rest of Europe Cancer Biologics Market Size
9. Company Profiles
9.1. AbbVie Inc.
9.1.1. AbbVie Inc. Snapshot
9.1.2. Company Overview
9.1.3. Product Offerings
9.1.4. AbbVie Inc.: Recent Initiatives, 2017 – 2020
9.1.5. Financial Performance (2015 – 2019)
9.1.5.1. Net Revenue (2015 – 2019)
9.1.5.2. Gross Profit (2015 – 2019)
9.1.5.3. Geographical Revenue, 2019
9.2. F.Hoffman La Roche
9.2.1. F.Hoffman La Roche Snapshot
9.2.2. Company Overview
9.2.3. Product Offerings
9.2.4. F.Hoffman La Roche: Recent Initiatives, 2017 – 2020
9.2.5. Financial Performance (2015 – 2019)
9.2.5.1. Net Revenue (2015 – 2019)
9.2.5.2. Gross Profit (2015 – 2019)
9.2.5.3. Geographical Revenue, 2019
9.3. GlaxoSmithKline
9.3.1. GlaxoSmithKline Snapshot
9.3.2. Company Overview
9.3.3. Product Offerings
9.3.4. GlaxoSmithKline: Recent Initiatives, 2017 – 2020
9.3.5. Financial Performance (2015 – 2019)
9.3.5.1. Net Revenue (2015 – 2019)
9.3.5.2. Gross Profit (2015 – 2019)
9.3.5.3. Geographical Revenue, 2019
9.4. Eli Lilly and Company
9.4.1. Eli Lilly and Company Snapshot
9.4.2. Company Overview
9.4.3. Product Offerings
9.4.4. Eli Lilly and Company: Recent Initiatives, 2017 – 2020
9.4.5. Financial Performance (2015 – 2019)
9.4.5.1. Net Revenue (2015 – 2019)
9.4.5.2. Gross Profit (2015 – 2019)
9.4.5.3. Geographical Revenue, 2019
9.5. Amgen
9.5.1. Amgen Snapshot
9.5.2. Company Overview
9.5.3. Product Offerings
9.5.4. Amgen: Recent Initiatives, 2017 – 2020
9.5.5. Financial Performance (2015 – 2019)
9.5.5.1. Net Revenue (2015 – 2019)
9.5.5.2. Gross Profit (2015 – 2019)
9.5.5.3. Geographical Revenue, 2019
9.6. Johnson & Johnson
9.6.1. Johnson & Johnson Snapshot
9.6.2. Company Overview
9.6.3. Product Offerings
9.6.4. Johnson & Johnson: Recent Initiatives, 2017 – 2020
9.6.5. Financial Performance (2015 – 2019)
9.6.5.1. Net Revenue (2015 – 2019)
9.6.5.2. Gross Profit (2015 – 2019)
9.6.5.3. Geographical Revenue, 2019
9.7. Merck & Co.
9.7.1. Merck & Co. Snapshot
9.7.2. Company Overview
9.7.3. Product Offerings
9.7.4. Merck & Co.: Recent Initiatives, 2017 – 2020
9.7.5. Financial Performance (2015 – 2019)
9.7.5.1. Net Revenue (2015 – 2019)
9.7.5.2. Gross Profit (2015 – 2019)
9.7.5.3. Geographical Revenue, 2019
9.8. Pfizer
9.8.1. Pfizer Snapshot
9.8.2. Company Overview
9.8.3. Product Offerings
9.8.4. Pfizer: Recent Initiatives, 2017 – 2020
9.8.5. Financial Performance (2015 – 2019)
9.8.5.1. Net Revenue (2015 – 2019)
9.8.5.2. Gross Profit (2015 – 2019)
9.8.5.3. Geographical Revenue, 2019
9.9. Other Notable Players
9.10. List of Companies Mentioned in this Report
10. Conclusion
10.1. Concluding Remarks
11. Glossary



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/



※注目の調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(VGA21MA032 )"世界のがん生物学的製剤市場2021-2031" (英文:Cancer Biologics Market Report 2021-2031)はvisiongain社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。